Resources Archive - Page 44 of 47

Engineered cell line panel complemented with in vivo models to enable next-generation target therapy discovery...

AACR Annual meeting 2021 Authors: Zhixiang Zhang1, Feifei Fan2, Xiaohe Shi2, Xiangyang Zuo2, Qingyang Gu2, Qunsheng Ji1. 1 WuXi AppTec,...

Establishment of drug induced resistant tumor models enable the development of next generation anticancer therapeutics

AACR Annual meeting 2021 Ting Ni, Zhixiang Zhang, Xuzhen Tang, Hui Qi, Jingying Zhang, Ke Mao, Wenting Shi, Qingyang Gu,...

Empowering Organic Syntheses with Quantum Mechanics Analyses

Syntheses of specifically functionalized molecules continue to be rate limiting steps (RLS) in drug discovery. Improvement in this RLS means...

The Synthesis of an Entrepreneur: Merging a Passion for Biochemistry, Synthetic Chemistry, and Bioactive Molecules...

INNOVATION THAT MATTERS By Rich Soll, Senior Advisor, Strategic Initiatives at WuXi AppTec (@richsollwx) Synthetic chemist Joseph Ready believes a...

Drug Hunter: Discovering New Frontiers in Cancer Treatments & Beyond

INNOVATION THAT MATTERS By Rich Soll, Senior Advisor, Strategic Initiatives at WuXi AppTec (@richsollwx) As a self-proclaimed drug hunter, Phil Jones is...

Faster with high-speed fragment screening — Accelerate your drug discovery campaign

In the past, thousands of proteins were considered undruggable. The restricted number of chemical entities available and classical methods limited...

Unlocking the potential of DEL | Inspire Hit Discovery

March 4, 2020 – By going commercial, DNA Encoded Library (DEL) technology facilitates rapid discovery and provides access to more chemical entities...

Enabling Technology for Targeted Protein Degradation

Summary Traditional small molecule therapeutic mechanisms have recently been augmented by a new strategy to specifically manipulate the levels of...

Establishment of KRAS-G12C inhibitor induced resistant tumor models enable the development of new generation KRAS-G12C...

Activating KRAS mutations, including G12C and G12D, are detected in approximately 25% of human cancers. The most common KRAS mutation...

Knowledge Library